TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26192892

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg QD for 4 weeks in IMs
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg QD for 4 weeks in PMs
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg QD for at least 4 weeks in EMs
Number of subjects: 42
Study: 23558370

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 40
Study: 21546601

Group type: COMPARATOR
Intervention: Cybertutor + Contact Group (Cy+C)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control Group (Control)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Brochure Group (Br)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cybertutor Group (Cy)
Number of subjects: 148
Study: 19287905

Group type: EXPERIMENTAL
Intervention: Strength training (ST) at 50-80% of one-repetition maximum (1-RM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-intensity general training (LGT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 35
Study: 16734584

Group type: EXPERIMENTAL
Intervention: subgingival chlorhexidine varnish
Number of subjects: 12

Group type: COMPARATOR
Intervention: same-day full-mouth root planing
Number of subjects: 12
Study: 15545844

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 100

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 100
Study: 11396752

Group type: EXPERIMENTAL
Intervention: Cisplatin plus fosfomycin (2 g fosfomycin twice daily for 5 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 13
Study: 9430254

Group type: EXPERIMENTAL
Intervention: Thalidomide at 100 mg/day for 24 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8487053

Group type: EXPERIMENTAL
Intervention: CPT-11 administered as a 100 mg/m2 weekly intravenous infusion or 150 mg/m2 every 2 weeks
Number of subjects: 67
Study: 3390053

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study: 30802208

Group type: EXPERIMENTAL
Intervention: Topical NAC (3 mL, 300 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systemic NAC (200 mg/kg once daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Topical + Systemic NAC (3 mL, 300 mg topical + 200 mg/kg systemic)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride-treated sterile gauze)
Number of subjects: 48
Study: 28058753

Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: glimepiride 2 mg
Number of subjects: 69
Study: 26599232

Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Pre-admission treatment types
Number of subjects: 155
Study: 23741491

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling and motivational interviewing according to the overweight prevention protocol (n = 349)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care (control condition, n = 288)
Number of subjects: 637
Study: 20581702

Group type: EXPERIMENTAL
Intervention: Variable ROM (VROM) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full ROM control (CON)
Number of subjects: 22
Study: 18155051

Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral block with 30 mL of mepivacaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment block with 30 mL of mepivacaine
Number of subjects: 48
Study: 16963388

Group type: EXPERIMENTAL
Intervention: Six-session relationship-based STD prevention intervention provided to the couple together
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Same intervention provided to the woman only
Number of subjects: 217

Group type: COMPARATOR
Intervention: Single-session education control provided to the woman only
Number of subjects: 217
Study: 15577438

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel (40-120 mg/m2/cycle for the first 10 patients, 100 mg/m2/cycle for the subsequent 13 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel
Number of subjects: 23
Study: 10811493

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with carboplatin AUC 7 every 28 days for six courses (n = 81)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Observation and chemotherapy at progression (Control group, n = 81)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups pooled for analysis of prognostic factors
Number of subjects: 162
Study: 8697160

Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril
Number of subjects: 19

Group type: COMPARATOR
Intervention: 5 mg lisinopril
Number of subjects: 19
Study: 1997305

Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (meglumine diatrizoate, Urografin 76%)
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Nonionic contrast medium (iopromide, Ultravist ‐370)
Number of subjects: 1153
Study: 6354600

Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 200 mg chlormezanone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chlormezanone (both doses)
Number of subjects: 31
Study: 29775246

Group type: EXPERIMENTAL
Intervention: Tramadol 400 mg (therapeutic dose) on days 1-3, tramadol 100 mg and moxifloxacin-matched placebo on day 4, placebo on all 4 days
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tramadol 600 mg (supratherapeutic dose) on days 1-3, tramadol 150 mg and moxifloxacin-matched placebo on day 4
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo on days 1-4 and moxifloxacin-matched placebo on day 4
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo on days 1-4 and moxifloxacin 400 mg on day 4
Number of subjects: 68
Study: 28799171

Group type: EXPERIMENTAL
Intervention: Denture group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-denture group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior reduced mandibular dental arches
Number of subjects: 0
Study: 26337213

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (1500 IU)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone (4 mg) and hyaluronidase (750 IU)
Number of subjects: 45
Study: 23364294

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice application)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 33
Study: 21300635

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19618383

Group type: EXPERIMENTAL
Intervention: Trauma-related questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontrauma questionnaires
Number of subjects: 0
Study: 17543174

Group type: EXPERIMENTAL
Intervention: Firebird sirolimus eluting stent
Number of subjects: 156

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 156
Study: 15084618

Group type: EXPERIMENTAL
Intervention: Calendula (Pommade au Calendula par Digestion; Boiron Ltd, Levallois‐Perret, France)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Trolamine (Biafine; Genmedix Ltd, France)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Calendula
Number of subjects: 254

Group type: COMPARATOR
Intervention: Trolamine
Number of subjects: 254
Study: 11531947

Group type: EXPERIMENTAL
Intervention: recombinant human interferon-gamma (rhIFNgamma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 10193493

Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bone scanning
Number of subjects: 22
Study: 8092207

Group type: EXPERIMENTAL
Intervention: Estradiol-releasing silicone rubber vaginal ring (6.5 to 9.5 micrograms per 24 hours)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ovesterin 0.5 mg estriol vaginal pessaries
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Estradiol-releasing silicone rubber vaginal ring
Number of subjects: 146

Group type: COMPARATOR
Intervention: Estriol vaginal pessaries
Number of subjects: 146
Study: 3385289

Group type: EXPERIMENTAL
Intervention: Stack splint
Number of subjects: 116

Group type: COMPARATOR
Intervention: Abouna splint
Number of subjects: 116
Study: 30669587

Group type: EXPERIMENTAL
Intervention: Quercetin (Q) 1000 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quercetin (Q)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 28318926

Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid followed by a continuous infusion of 1 mg/kg/h until the end of surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25937378

Group type: EXPERIMENTAL
Intervention: Dominant hand placement against the sternum
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nondominant hand placement against the sternum
Number of subjects: 101
Study: 23648395

Group type: EXPERIMENTAL
Intervention: DASH diet intervention (8 group and 3 individual sessions over 3 months, followed by monthly phone consultations for another 3 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 90
Study: 21278551

Group type: EXPERIMENTAL
Intervention: Internet-based patient education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face patient education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both education methods
Number of subjects: 0
Study: 19624605

Group type: EXPERIMENTAL
Intervention: FFP-male
Number of subjects: 82

Group type: COMPARATOR
Intervention: FFP-mixed
Number of subjects: 82
Study: 16989830

Group type: EXPERIMENTAL
Intervention: Embryos derived from brown oocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Embryos derived from morphologically normal oocytes
Number of subjects: 0
Study: 15062148

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 149
Study: 10799374

Group type: EXPERIMENTAL
Intervention: 6 g AX-rich fiber
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 12 g AX-rich fiber
Number of subjects: 14

Group type: COMPARATOR
Intervention: AX-rich fiber bread
Number of subjects: 14
Study: 8819606

Group type: EXPERIMENTAL
Intervention: Hand switch
Number of subjects: 72

Group type: COMPARATOR
Intervention: Head switch
Number of subjects: 72
Study: 1479562

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Passive tube drainage
Number of subjects: 36
Study: 4080297

Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2C monotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2C
Number of subjects: 42
Study: 30953768

Group type: EXPERIMENTAL
Intervention: Endotoxin injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study: 30693884

Group type: EXPERIMENTAL
Intervention: Fletcher's applicator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Henschke applicator
Number of subjects: 50
Study: 27005961

Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (1800 mg of eicosapentaenoic acid and docosahexaenoic acid per day for 6 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline gene expression
Number of subjects: 23

Group type: COMPARATOR
Intervention: Gene set enrichment analysis
Number of subjects: 23
Study: 24766971

Group type: EXPERIMENTAL
Intervention: Nicotine 1mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nicotine 2mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22805467

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21280458

Group type: EXPERIMENTAL
Intervention: True acupoint electrical stimulation (EG1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sham acupoint stimulation (EG2)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No acupoint intervention (CG)
Number of subjects: 99
Study: 18940119

Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 12 weeks (Group-I, n=81)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-II, n=81)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-III, n=65)
Number of subjects: 227
Study: 15857840

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fluorouracil-based first-line chemotherapy in patients with non-mucinous CRC (control group)
Number of subjects: 135
Study: 12551866

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 to 60 mg/d
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Nifedipine and cerivastatin combination
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/d
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 9871860

Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.12% twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.12% three times daily
Number of subjects: 36
Study: 7847298

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (6 million units three times/wk for 6 months) plus ursodeoxycholic acid (10 mg/kg/day for 9 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interferon-alpha (6 million units three times/wk for 6 months) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interferon-alpha + UDCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 40
Study: 2140970

Group type: EXPERIMENTAL
Intervention: 1,500 mg of acetyl-L-carnitine for 45 days
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 469
Study: 354397

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 0
Study: 30986536

Group type: EXPERIMENTAL
Intervention: MINIMAL or INTENSE intervention components delivered face-to-face or via telephone by Patient Navigators (PN)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Use of pharmacologic support for abstinence (NRT)
Number of subjects: 254

Group type: COMPARATOR
Intervention: No specific intervention groups
Number of subjects: 254
Study: 28474783

Group type: EXPERIMENTAL
Intervention: Peri-implant probing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Periodontal probing
Number of subjects: 80
Study: 26397087

Group type: EXPERIMENTAL
Intervention: Tethered-kicking intervention
Number of subjects: 16
Study: 22311104

Group type: EXPERIMENTAL
Intervention: Avoidant attachment and emotion-focused coping
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Avoidant and insecure attachment styles
Number of subjects: 94
Study: 21987709

Group type: EXPERIMENTAL
Intervention: School-based influenza vaccination intervention
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Provider-based influenza vaccination intervention
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard-of-care condition
Number of subjects: 370
Study: 17932967

Group type: EXPERIMENTAL
Intervention: Active diet (highly restricted diet based on spelt bread and red meat)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet (low-fiber, low-fat, high-carbohydrate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (Active and Control)
Number of subjects: 18
Study: 16931685

Group type: EXPERIMENTAL
Intervention: Capsicum plaster (PAS) at Zusanli acupoints
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo tape at Zusanli acupoints
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham treatment (PAS at nonacupoints on shoulders)
Number of subjects: 90
Study: 12897277

Group type: EXPERIMENTAL
Intervention: 21% O2
Number of subjects: 591

Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 591
Study: 11167470

Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.5 MAC supplemented with remifentanil (0.34 microg x kg(‐1) x min(‐1))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC supplemented with remifentanil (0.25 microg x kg(‐1) x min(‐1))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5 MAC supplemented with remifentanil (0.21 microg x kg(‐1) x min(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sevoflurane only (control group)
Number of subjects: 80
Study: 9551018

Group type: EXPERIMENTAL
Intervention: Public-private certified nurse-midwife program
Number of subjects: 0
Study: 7904489

Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF at a dose of 125 micrograms/m2/d by continuous intravenous infusion (group 2)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF at a dose of 250 micrograms/m2/d by continuous intravenous infusion (group 3)
Number of subjects: 144

Group type: COMPARATOR
Intervention: PBC collected without mobilization (group 1)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF mobilization
Number of subjects: 144
Study: 2756602

Group type: EXPERIMENTAL
Intervention: Arthroscopic procedure with partial meniscectomie
Number of subjects: 160

Group type: COMPARATOR
Intervention: Arthrotomie and partial meniscectomie
Number of subjects: 160
Study: 8062862

Group type: EXPERIMENTAL
Intervention: Active treatment with a pause of 2-3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous active treatment without interruption
Number of subjects: 40
Study: 380427

Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1.00 to 1.67 mg) administered at a rate of 0.5 mg/min every 4 min.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.102 to 0.238 mg/kg body weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1.00 to 1.67 mg)
Number of subjects: 8
Study: 30592991

Group type: EXPERIMENTAL
Intervention: ipatasertib/mFOLFOX6
Number of subjects: 153

Group type: COMPARATOR
Intervention: placebo/mFOLFOX6
Number of subjects: 153
Study: 29696922

Group type: EXPERIMENTAL
Intervention: Acupuncture at Weishu (BL 21)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acupuncture at combined Weishu (BL 21) and Zhongwan (CV 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acupuncture at combined front‐mu and back‐shu points
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 26582315

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal/iliohypogastric nerve block (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nerve block, Group NB)
Number of subjects: 40
Study: 25426142

Group type: EXPERIMENTAL
Intervention: Chewing gum containing sorbitol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing xylitol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing a mixture of sorbitol and xylitol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paraffin (control)
Number of subjects: 12
Study: 22483445

Group type: EXPERIMENTAL
Intervention: Torus mandibularis bone chips combined with PRP gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Torus mandibularis bone chips alone
Number of subjects: 12
Study: 19347685

Group type: EXPERIMENTAL
Intervention: EGb 761(R) (240 mg per day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Donepezil (initially 5 mg, after 4 weeks 10 mg per day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination treatment (EGb 761(R) and donepezil at the same doses)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Donepezil mono-therapy
Number of subjects: 96
Study: 17497280

Group type: EXPERIMENTAL
Intervention: tirofiban+heparin
Number of subjects: 200

Group type: COMPARATOR
Intervention: heparin
Number of subjects: 200
Study: 14693783

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Deep sclerectomy (DS)
Number of subjects: 104
Study: 11984209

Group type: EXPERIMENTAL
Intervention: DM-training
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DM-exposure
Number of subjects: 103

Group type: COMPARATOR
Intervention: DM
Number of subjects: 103
Study: 9818851

Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 171

Group type: COMPARATOR
Intervention: Identical placebos
Number of subjects: 171
Study: 7859897

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice a day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2760170

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (100 micrograms)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6161

Group type: EXPERIMENTAL
Intervention: Timolol 30 to 60 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol 240 to 480 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31392559

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg/day for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54